Intellikine, Inc.: 3D Structure of Key Drug Target Sheds Light on How to Design Better Drugs

LA JOLLA, Calif., Jan. 12 /PRNewswire/ -- Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.

The pioneering work was the result of a collaboration led by Roger Williams, Ph.D., Professor in the Laboratory of Molecular Biology at the Medical Research Council in Cambridge, U.K., and it included scientists from the University of California, San Francisco, Intellikine in La Jolla, California, and Merck-Serono Research Center in Geneva, Switzerland.

"We believe that the discovery of isoform-selective inhibitors is critical if chronic treatment with kinase inhibitors is to become reality," added Christian Rommel, Ph.D., Chief Scientific Officer of Intellikine. "Over the past several years, we have exploited the insights from these co-crystal structures to design multiple series of isoform-selective inhibitors, and this work was instrumental to our designing INK1197, an exquisitely selective inhibitor which we are advancing as a therapy for inflammatory and respiratory disease."

About Intellikine

Intellikine, Inc.